Biogen Idec Inc., a Weston-based biotechnology company known for its multiple sclerosis drugs, said it has submitted a New Drug Application to federal regulators to get approval to market a potential new MS treatment known as BG-12.
In December, Biogen Idec shares hit their high for 2011 after the company released promising results from a clinical trial of BG-12.
BG-12, the company’s designation for dimethyl fumarate, would be taken twice a day in pill form, and it is designed to treat of relapsing-remitting multiple sclerosis, sometimes called RRMS, the most common form of MS, Biogen Idec said in a press release.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679